The protocol at a glance
No dose has been tested in people. The only papers I found are lab work on cells and computer models.
| Item | Finding |
|---|---|
| Human dose | Not established |
| Studied in | Cell cultures and computer models; no animal dosing study found |
| Name clash | ClinicalTrials.gov NCT02733133 'Testagen TDS-Testosterone' is a different, testosterone product with a similar name |
Searches of PubMed and ClinicalTrials.gov. I found no Testagen-specific human or animal dosing paper, so there is no schedule to report.
Community reports commonly describe 100-300 mcg a day for 10-20 days.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing
No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.
What the trials found
There are no human results, so these are the evidence facts, all from lab or computer work:
Biochemistry (Moscow) 2011 (PMID 22117547); Biomolecules 2023 (PMID 36979488). A 2020 review lists KEDG among peptides said to stimulate immune cell differentiation (PMID 31808038); I did not check the primary data behind that line.
Side effects
- Safety in people is unknown. No dosing study was found.
How it works
Gene-control theory
The research group proposes that short peptides enter the cell nucleus and bind DNA to adjust gene activity. In lab work Testagen did enter cells and interacted with DNA pieces, but this has not been shown to raise testosterone.
Sources
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells, Biochemistry (Mosc) 2011, PMID 22117547
- Feasibility of transport of 26 ultrashort peptides via LAT and PEPT transporters, Biomolecules 2023, PMID 36979488
- Peptide regulation of cell differentiation, Stem Cell Rev Rep 2020, PMID 31808038
- ClinicalTrials.gov NCT02733133 (different product, name clash)